{"disease":{"id":"symptom-assessment","name":"symptom assessment"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06846957","title":"ESSENCE is a Quality Improvement Study That Evaluates the Impact of Ada's AI-powered Core Symptom Assessment Technology on Clinical Workflow and Individual Healthcare Guidance, Following the November 2021 Integration of the Tool Into the CUF Hospital Network. Study Duration Nov 2024-Oct 2025","phase":"","overall_status":"COMPLETED","enrollment_count":1470,"lead_sponsor_name":"Ada Health GmbH","has_results":false},{"nct_id":"NCT07396142","title":"BaiXiaoAi AI Companion for Cancer Patient Follow-up","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}